Semapimod

Drug Profile

Semapimod

Alternative Names: AXD-455; CN-1493; CNI 1493; CPSI-2364; Semapimod salt

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Picower Institute for Medical Research
  • Developer Cytokine PharmaSciences; GPC Biotech AG
  • Class Anti-inflammatories; Hydrazones; Small molecules
  • Mechanism of Action Cytokine inhibitors; HIV replication inhibitors; Immunomodulators; Interleukin 1 inhibitors; Interleukin 6 inhibitors; Mitogen-activated protein kinase inhibitors; Nitric oxide inhibitors; Raf kinase inhibitors; RNA inhibitors; Tumour necrosis factor alpha inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Inflammation
  • Discontinued Chemotherapy-induced damage; Crohn's disease; HIV infections; Pancreatitis; Psoriasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (PO)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top